Exelixis, Inc. (EXEL) Receives Average Recommendation of “Buy” from Analysts

Shares of Exelixis, Inc. (NASDAQ:EXEL) have been assigned an average recommendation of “Buy” from the fourteen brokerages that are covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $29.76.

A number of brokerages have weighed in on EXEL. Zacks Investment Research lowered Exelixis from a “buy” rating to a “hold” rating in a research note on Monday, February 11th. BidaskClub lowered Exelixis from a “buy” rating to a “hold” rating in a research note on Tuesday. Cowen restated a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research note on Tuesday, February 26th. ValuEngine upgraded Exelixis from a “sell” rating to a “hold” rating in a research note on Wednesday, January 9th. Finally, Oppenheimer restated a “buy” rating on shares of Exelixis in a research note on Tuesday, March 19th.

Shares of EXEL opened at $21.36 on Thursday. The stock has a market cap of $6.89 billion, a P/E ratio of 14.94, a P/E/G ratio of 0.46 and a beta of 2.21. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.41 and a current ratio of 8.50. Exelixis has a 52-week low of $13.42 and a 52-week high of $25.31.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 12th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.14. The business had revenue of $228.60 million for the quarter, compared to analysts’ expectations of $188.44 million. Exelixis had a return on equity of 48.90% and a net margin of 80.95%. The firm’s quarterly revenue was up 90.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.12 EPS. As a group, research analysts expect that Exelixis will post 1.08 EPS for the current year.

In other news, Director Vincent T. Marchesi sold 41,250 shares of the stock in a transaction dated Friday, February 22nd. The stock was sold at an average price of $21.50, for a total transaction of $886,875.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Michael Morrissey sold 40,000 shares of the stock in a transaction dated Wednesday, January 30th. The shares were sold at an average price of $23.12, for a total value of $924,800.00. The disclosure for this sale can be found here. Insiders sold a total of 1,004,101 shares of company stock worth $22,946,624 over the last 90 days. Corporate insiders own 4.80% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. James Investment Research Inc. increased its position in shares of Exelixis by 875.3% during the 4th quarter. James Investment Research Inc. now owns 60,225 shares of the biotechnology company’s stock valued at $1,185,000 after purchasing an additional 54,050 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Exelixis by 8.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,931,216 shares of the biotechnology company’s stock valued at $105,101,000 after purchasing an additional 480,986 shares during the last quarter. Oakbrook Investments LLC increased its position in shares of Exelixis by 213.9% during the 4th quarter. Oakbrook Investments LLC now owns 36,100 shares of the biotechnology company’s stock valued at $710,000 after purchasing an additional 24,600 shares during the last quarter. Blume Capital Management Inc. bought a new position in shares of Exelixis during the 4th quarter valued at about $152,000. Finally, Oregon Public Employees Retirement Fund increased its position in shares of Exelixis by 1,978.9% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 2,319,939 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 2,208,347 shares during the last quarter. Hedge funds and other institutional investors own 75.95% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Article: Cost of Equity For A Business, Investors

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.